Elias Jabbour, MD, and Dennis Kim, MD, discuss recent data for olverembatininb and its place in CML management.
Dennis Kim, MD
Advertisement
Kim is an associate professor at the Institute of Medical Science at the University of Toronto in Canada.
Articles by Dennis Kim, MD
Advertisement
Latest Updated Articles
Unpacking Data and Upcoming Developments for Olverembatinib in CMLSeptember 29th 2026
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Durvalumab Plus Enfortumab Vedotin for Cisplatin-Ineligible MIBC
2
Dr Gleave on Selecting Patients for Perioperative Therapy in High-Risk Prostate Cancer
3
Dr Calais on Individualizing PSMA-Targeted Therapy Sequencing in Prostate Cancer
4
Cardiovascular and Bleeding Risk With BTK Inhibitors in CLL
5